10 studies found for:    AGS-003
Show Display Options
Rank Status Study
1 Enrolling by invitation A Rollover Protocol for Subjects Previously Treated With AGS-003
Condition: Renal Cell Carcinoma
Intervention: Drug: AGS-003
2 Recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Conditions: Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment;   Biological: AGS-003
3 Recruiting Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer
Interventions: Biological: renal cell carcinoma/CD40L RNA-transfected autologous dendritic cell vaccine AGS-003;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
4 Completed Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Condition: Renal Cell Carcinoma
Interventions: Biological: AGS-003;   Drug: Sunitinib
5 Completed Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
Condition: Renal Cell Carcinoma
Intervention: Biological: AGS-003
6 Recruiting RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)
Condition: Metastatic Renal Cell Carcinoma
Intervention: Device: RNA extraction and amplification from biopsy specimens
7 Completed AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: AGS-1C4D4
8 Active, not recruiting Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
Condition: HIV Infection
Interventions: Biological: AGS-004;   Biological: Placebo
9 Completed A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
Conditions: HIV Seropositivity;   Acquired Immunodeficiency Syndrome
Intervention: Biological: AGS-004
10 Recruiting Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
Condition: Clostridium Difficile Infection
Interventions: Biological: C. difficile Toxoid Vaccine;   Biological: Placebo: 0.9% normal saline

Indicates status has not been verified in more than two years